Quantcast

Latest Antibody Stories

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2014-01-13 04:21:01

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody(TM) research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept...

2014-01-10 12:25:56

SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present a corporate overview at the following events next week in San Francisco: Event: Biotech Showcase 2014 When: Monday, January 13, 2014 at 3:00 PM PT Parc 55 Wyndham San...

2014-01-10 08:23:51

First-in-class program for the treatment of atopic dermatitis and allergic diseases SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the development of a first-in-class therapeutic antibody to interleukin-33 (IL-33). Discovered using the Company's proprietary SHM-XEL platform, AnaptysBio's anti-IL-33 lead candidate antibody (ANB020) inhibits IL-33 cytokine function by blocking interaction with its receptor at...

2014-01-07 08:32:18

SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the...

2014-01-06 10:17:40

Earlier amyloid-beta assemblies may be one of the most important causes of Alzheimer's disease. Passive immunization of anti-amyloid-beta antibodies can reduce amyloid-beta burden and improved memory performance in various Alzheimer's disease animal models or patients. Screening humanized antibodies from a human Fab phage display library is an effective and quick method to obtain beta-amyloid oligomers. Thus, a recent study published in the Neural Regeneration Research (Vol. 8, No. 33, 2013)...

Boosting A Malaria Vaccine
2013-12-27 12:34:32

Brett Smith for redOrbit.com - Your Universe Online According to a study published in the journal PLOS Pathogens on Thursday, a prominent malaria vaccine could be drastically improved by utilizing the right mix of proteins taken from the surface of the virus. The study researchers focused on the virus’ AMA1 protein, which the human body recognizes and uses to stimulate an immune response. However, the protein exists in multiple strains – causing problems for researchers looking to...

2013-12-19 23:23:22

St. George’s to Utilize DNA2.0’s GeneGPS® Expression Technology to Increase Protein Expression in Tobacco for the Production of Therapeutic Antibodies Menlo Park, Calif. (PRWEB) December 19, 2013 DNA2.0 has entered into a research collaboration with the Infection and Immunity Research Centre at St. George’s, University of London, to support the development of plant-based biopharmaceuticals. Professor Julian Ma and his research group at St. George’s have made significant...

2013-12-19 10:35:03

A newly identified immune protein influences each person's response to vaccines and risk for autoimmune diseases like lupus and multiple sclerosis, according to a study published today by researchers from the School of Medicine at the University of Alabama at Birmingham in the journal Science Translational Medicine. The protein, called a receptor and part of signaling pathways, also provides a new target for personalized therapies for patients with autoimmune diseases. The research team...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related